Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
921-940 of 1,738 trials

Glibenclamide for High Blood Sugar in Premature Infants

We are studying whether an oral suspension of glibenclamide can help control high blood sugar in premature infants under 1500 grams. The trial will also look at its safety and effects on growth.

Neonatal Hyperglycemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyPediatrics

Advanced Solid Tumors: ORIC-114 Study

We are testing a new drug, ORIC-114, for patients with advanced solid tumors that have EGFR or HER2 alterations. The study will assess its safety and effectiveness alone and with chemotherapy.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Myeloma: SABLe Study with Selinexor

We are investigating a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The study aims to evaluate how well the treatment works and its effects on quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Advanced Lung Cancer: Amivantamab and Lazertinib Study

We are exploring a new treatment combination for people with advanced non-small cell lung cancer who have an EGFR mutation and have not responded to earlier therapies. The goal is to see if this combination can improve treatment outcomes and safety.

Advanced Non-Small Cell Lung Cancer (NSCLC)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Head and Neck Cancer: Carboplatin, Paclitaxel, and Cetuximab Study

We are studying a combination of three medications for patients with recurrent or metastatic head and neck squamous cell carcinoma who did not respond to previous treatments. The goal is to see if this combination improves response rates and overall survival.

Head and Neck Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Amantadine for Improving Alertness in ICU Patients

We are studying whether Amantadine can enhance responsiveness in patients receiving intensive care. The trial will measure changes in alertness over several days using established clinical scoring systems.

Unresponsive Wakefulness Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Solid Tumors: MCLA-128 Treatment Study

We are studying a new bispecific antibody, MCLA-128, in patients with solid tumors that have an NRG1 fusion. The goal is to evaluate its safety and how well it may work against these tumors.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chemotherapy and Immunotherapy for Pancoast Tumor in Lung Cancer

We are studying the effects of chemotherapy and immunotherapy before and after surgery in patients with non-small cell lung cancer located in the upper part of the lungs. The goal is to see if this approach improves survival and treatment outcomes.

Pancoast's TumorEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Breast Cancer: Trastuzumab Deruxtecan vs. CDK4/6 Inhibitors

We are studying whether trastuzumab deruxtecan is more effective than a combination of CDK4/6 inhibitors and endocrine therapy for patients with HR-positive, HER2-low advanced breast cancer. This research aims to improve treatment options for this specific group of patients.

Locally Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOncology

Small-Cell Lung Cancer: Durvalumab and Olaparib Maintenance Therapy

We are studying the effects of a combination of durvalumab and olaparib for patients with HRD-positive extensive disease small-cell lung cancer after initial treatment. The goal is to see if this maintenance therapy improves outcomes and is safe for patients.

Extensive Stage Small Cell Lung Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

Duchenne Muscular Dystrophy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyNeurologyPediatrics

Advanced Cancer: JK06 Antibody Drug

We are testing a new drug called JK06 for patients with advanced cancer that cannot be removed by surgery. The study aims to evaluate its safety and how well it may work in treating this type of cancer.

Unresectable, Locally Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboOncology

Gastrointestinal Cancers: Patritumab Deruxtecan Study

We are evaluating a new treatment for people with gastrointestinal cancers to see if it is safe and effective. This study aims to understand how well it works compared to existing options.

Colorectal CancerHepatocellular CarcinomaBiliary Tract Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOncology

Buprenorphine for Severe Suicidal Thoughts in Major Depression

We are studying whether buprenorphine can help reduce severe suicidal ideas in individuals with major depressive episodes. The trial will compare different doses to find the most effective and safest option.

Clinical Depression≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPsychiatry

Chronic Depression: Ketamine Treatment Study

We are investigating whether adding ketamine to a therapy for chronic depression can reduce symptoms more effectively than a placebo. This study aims to help improve treatment options for those struggling with depression.

Chronic Depression≤3 monthsEfficacy phase (II)Standard MedicinesPsychiatry

CRISPR CAR Therapy for Blood and Solid Cancers

We are studying the long-term safety and effectiveness of CRISPR CAR cellular therapies in patients with hematological and solid malignancies. This research aims to provide insights into how well this treatment works over time.

Solid TumorsHematologic Malignancies>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Liver Cancer: Hyperpolarized Pyruvate MRI Study

We are exploring whether a new MRI technique can help detect small liver tumors earlier in people at risk for hepatocellular carcinoma. This may improve early diagnosis and treatment options.

Primary Liver Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

Chronic Kidney Disease: Ultra-Sensitive MRI Study

We are investigating how advanced MRI can detect metabolic changes in patients with chronic kidney disease and polycystic kidney disease. This research may help improve diagnosis and treatment monitoring.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)Chronic Kidney Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Glioblastoma: Dendritic Cell Vaccine Study

We are testing a personalized vaccine made from your own immune cells and tumor tissue for patients with glioblastoma. The study aims to see if this treatment can improve safety and help patients live longer without disease progression.

Glioblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Cochlear Implant Surgery: Testing VSF1.01 Treatment

We are investigating the safety of a new treatment for patients receiving cochlear implants. This study aims to see if it can reduce surgery-related trauma and improve hearing outcomes.

Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboOtolaryngology